RG
BSX icon

Rathbones Group’s Boston Scientific BSX Stock Holding History

Rathbones Group’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108M Sell
2,539,901
-639,534
-20% -$34.7M 0.4% 55
2026
Q1 		$200M Buy
3,179,435
+419,778
+15% +$33.6M 0.8% 30
2025
Q4 		$263M Buy
2,759,657
+477,680
+21% +$46.8M 1.03% 23
2025
Q3 		$223M Buy
2,281,977
+31,529
+1% +$3.27M 0.9% 27
2025
Q2 		$242M Sell
2,250,448
-88,943
-4% -$9M 1.04% 24
2025
Q1 		$236M Sell
2,339,391
-56,187
-2% -$5.66M 1.14% 21
2024
Q4 		$214M Sell
2,395,578
-9,880
-0.4% -$870K 1.04% 24
2024
Q3 		$202M Sell
2,405,458
-1,728
-0.1% -$136K 1.02% 23
2024
Q2 		$185M Buy
2,407,186
+53,770
+2% +$3.94M 1.01% 23
2024
Q1 		$161M Buy
2,353,416
+7,948
+0.3% +$511K 0.93% 26
2023
Q4 		$136M Buy
2,345,468
+82,646
+4% +$4.41M 0.87% 29
2023
Q3 		$119M Buy
2,262,822
+260,964
+13% +$13.7M 0.87% 30
2023
Q2 		$108M Buy
2,001,858
+556,884
+39% +$29.1M 1.01% 26
2023
Q1 		$72.3M Sell
1,444,974
-3,022
-0.2% -$142K 0.74% 42
2022
Q4 		$67M Sell
1,447,996
-2,779
-0.2% -$120K 0.75% 38
2022
Q3 		$56.2M Buy
+1,450,775
New +$58.2M 0.69% 40
2021
Q4 		– Sell
-6,245
Closed -$271K – 426
2021
Q3 		$271K Buy
+6,245
New +$276K ﹤0.01% 365
2021
Q1 		– Sell
-23,745
Closed -$854K – 407
2020
Q4 		$854K Sell
23,745
-169,940
-88% -$6.12M 0.01% 242
2020
Q3 		$7.4M Sell
193,685
-5,000
-3% -$193K 0.13% 104
2020
Q2 		$6.98M Buy
198,685
+25,205
+15% +$908K 0.14% 100
2020
Q1 		$5.66M Sell
173,480
-750,520
-81% -$29.3M 0.16% 95
2019
Q4 		$41.8M Buy
924,000
+109,979
+14% +$4.6M 1.1% 30
2019
Q3 		$33.1M Buy
814,021
+22,650
+3% +$960K 0.94% 40
2019
Q2 		$34M Buy
791,371
+658,328
+495% +$25.3M 1.06% 32
2019
Q1 		$5.11M Buy
133,043
+3,151
+2% +$120K 0.17% 98
2018
Q4 		$4.59M Buy
129,892
+51,821
+66% +$1.88M 0.18% 97
2018
Q3 		$3.01M Buy
+78,071
New +$2.73M 0.1% 111

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Rathbones Group's BSX Position: Q2 2026 in Review

Rathbones Group reduced its Boston Scientific (BSX) stake by 20% in Q2 2026, selling an estimated $34.7M and leaving 2,539,901 shares worth $108M. The position accounts for 0.4% of the portfolio, ranked #55.

Rathbones Group first reported a position in BSX in Q3 2018 and has held it in 27 quarters since. The position peaked at $263M in Q4 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Rathbones Group held 2,539,901 shares of Boston Scientific worth $108M as of Q2 2026.
  • Rathbones Group sold 639,534 Boston Scientific shares in Q2 2026, an estimated $34.7M.
  • Boston Scientific made up 0.4% of Rathbones Group's portfolio in Q2 2026, its #55 holding.
  • Rathbones Group first reported a position in Boston Scientific in Q3 2018 and has held it in 27 quarters since.
  • Rathbones Group's Boston Scientific position peaked at $263M in Q4 2025.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.